Haleos Labs (HALEOSLABS) Stock Overview
Engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
HALEOSLABS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Haleos Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,386.80 |
| 52 Week High | ₹1,680.00 |
| 52 Week Low | ₹959.80 |
| Beta | 0.27 |
| 1 Month Change | 9.76% |
| 3 Month Change | 15.68% |
| 1 Year Change | 15.86% |
| 3 Year Change | 108.13% |
| 5 Year Change | 127.61% |
| Change since IPO | 928.40% |
Recent News & Updates
There Is A Reason Haleos Labs Limited's (NSE:SMSLIFE) Price Is Undemanding
Nov 15
Here's Why Shareholders May Want To Be Cautious With Increasing Haleos Labs Limited's (NSE:SMSLIFE) CEO Pay Packet
Sep 24Recent updates
There Is A Reason Haleos Labs Limited's (NSE:SMSLIFE) Price Is Undemanding
Nov 15Here's Why Shareholders May Want To Be Cautious With Increasing Haleos Labs Limited's (NSE:SMSLIFE) CEO Pay Packet
Sep 24Is SMS Lifesciences India (NSE:SMSLIFE) Using Too Much Debt?
Jul 18The Market Doesn't Like What It Sees From SMS Lifesciences India Limited's (NSE:SMSLIFE) Earnings Yet
Apr 05Earnings Working Against SMS Lifesciences India Limited's (NSE:SMSLIFE) Share Price Following 25% Dive
Nov 14Improved Earnings Required Before SMS Lifesciences India Limited (NSE:SMSLIFE) Stock's 58% Jump Looks Justified
Aug 27Is SMS Lifesciences India (NSE:SMSLIFE) Using Too Much Debt?
Aug 01SMS Lifesciences India Limited (NSE:SMSLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Market
Jun 13SMS Lifesciences India (NSE:SMSLIFE) Use Of Debt Could Be Considered Risky
Feb 10There's Reason For Concern Over SMS Lifesciences India Limited's (NSE:SMSLIFE) Massive 30% Price Jump
Jan 05Should Shareholders Reconsider SMS Lifesciences India Limited's (NSE:SMSLIFE) CEO Compensation Package?
Sep 23SMS Lifesciences India (NSE:SMSLIFE) Is Paying Out A Dividend Of ₹1.50
Sep 07SMS Lifesciences India (NSE:SMSLIFE) Has Affirmed Its Dividend Of ₹1.50
Aug 24SMS Lifesciences India (NSE:SMSLIFE) Will Pay A Dividend Of ₹1.50
Sep 16SMS Lifesciences India (NSE:SMSLIFE) Will Pay A Dividend Of ₹1.50
Sep 02SMS Lifesciences India (NSE:SMSLIFE) Takes On Some Risk With Its Use Of Debt
Jun 03With EPS Growth And More, SMS Lifesciences India (NSE:SMSLIFE) Is Interesting
May 13SMS Lifesciences India's (NSE:SMSLIFE) Solid Profits Have Weak Fundamentals
Nov 23Is Now The Time To Put SMS Lifesciences India (NSE:SMSLIFE) On Your Watchlist?
Jun 21Is SMS Lifesciences India (NSE:SMSLIFE) Using Too Much Debt?
Feb 22SMS Lifesciences India Limited's (NSE:SMSLIFE) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Jan 04Insider Buying: The SMS Lifesciences India Limited (NSE:SMSLIFE) MD & Executive Director Just Bought 19% More Shares
Nov 27Does SMS Lifesciences India (NSE:SMSLIFE) Have A Healthy Balance Sheet?
Nov 24Shareholder Returns
| HALEOSLABS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.9% | -0.4% | -0.3% |
| 1Y | 15.9% | -2.2% | -2.3% |
Return vs Industry: HALEOSLABS exceeded the Indian Pharmaceuticals industry which returned -2.5% over the past year.
Return vs Market: HALEOSLABS exceeded the Indian Market which returned -2.8% over the past year.
Price Volatility
| HALEOSLABS volatility | |
|---|---|
| HALEOSLABS Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.6% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: HALEOSLABS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: HALEOSLABS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 592 | Talluri Veera Venkata Murthy | www.smslife.in |
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products.
Haleos Labs Limited Fundamentals Summary
| HALEOSLABS fundamental statistics | |
|---|---|
| Market cap | ₹4.19b |
| Earnings (TTM) | ₹186.98m |
| Revenue (TTM) | ₹3.38b |
Is HALEOSLABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HALEOSLABS income statement (TTM) | |
|---|---|
| Revenue | ₹3.38b |
| Cost of Revenue | ₹2.11b |
| Gross Profit | ₹1.27b |
| Other Expenses | ₹1.08b |
| Earnings | ₹186.98m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 61.85 |
| Gross Margin | 37.61% |
| Net Profit Margin | 5.54% |
| Debt/Equity Ratio | 30.4% |
How did HALEOSLABS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/12 03:23 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Haleos Labs Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |